medigraphic.com

2002, Number 2

<< Back Next >>

Cir Cir 2002; 70 (2)

Desmopressin tablets in treatment of patients with central diabetes insipidus

Mendoza-Morfín F, Cárdenas-Tirado H, Montero-González P, Bravo-Ríos LE, Gutiérrez-Ávila C, Torres TM, Pérez-Olea MV

Language: Spanish
References: 22
Page: 93-97
PDF size: 85.03 Kb.


ABSTRACT

Objective: To assess desmopressin tablet efficiency and safety related to treatment of central diabetes insipidus patients compared with intranasal administration. Matherial and methods: Twenty five central diabetes insipidus patients were included, 20 men and five women, with age mean of 12.7 ± 3.8 years standard deviation (SD) and 9.6 ± 3.6 years, respectively. All were treated with intranasal desmopressin. After 24 h of desensitization, desmopressin tablets at a proportion of 1:20 with respect to intranasal presentation was begun every 8 or 12h depending on urinary volumes. This phase was continued during 6 months. Twenty one patients proceeded into a second phase of tablet treatment after intranasal desmopressin reinstallation. This time, tablet do ses were adjusted after 72 h of knowing urinary volume and osmolarity, with follow-up at 2, 4, 6, and 8 weeks of treatment. Results: On comparing urinary volumes of oral against intranasal doses an increase was observed (927.7 ± 267.3 vs 1,085.4 ± 450.2 ml/m2 BS, p = Ns), with urinary osmolarity showing a slight decrease (508.3 ± 263.6 vs 333.3 ± 162.2 mOsm/kg, p = Ns). However, neither difference was statistically significant. In the second phase, mean desmopressin tablet doses were 530.9 ± 212.4 µg/day. Urinary volumes had aslight increase (1,012.7 ± 461.4 vs 1,254.7 ± 732.7 ml/m2 BS, p = Ns), with urinary osmolarity increasing to 340.7 ± 161.6 vs 365.3 ± 194.5 ml/m2 Bs, p = Ns). As before, neither difference was statistically significant. The desmopressin tablet preparation showed to be effective and safe. This is a good alternative to treat central diabetes insipidus in patients when specifically compared to intranasal solution in patients with acute or chronic nasal mucous inflammation.


REFERENCES

  1. Zaoral M, Kolc J, Sorm S. Aminoacids and peptides LXXI. Synthesis of 1-desamino-8-D-y-amino-uterine vasopressin, 1-deamino-8-D-lysine-vasopressin and 1-deamino-8-D-arginine vasopressin. Collect Czech Chem Commun 1967;32:1250-7.

  2. Seif SM, Zenser TV, Ciarochi FF, Davis BB, Robinson AG. DDA VP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus-mechanism of prolonged antidiuresis. J Clin Endocrinol Metab 1978;46:381-8.

  3. Schlondorff D, Franki N. Effect of vasopressin on cyclic AMP-dependent protein kinase in toad urinary bladder. Biochem Biophys Acta 1980;628:1-12.

  4. Fjellestad-Paulsen A, Tubiana-Rufi N, Harris A, Czernichow P. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. Acta Endocrinol (Copenh) 1987;115:307-12.

  5. Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect of F VIII/v WF, pharmacokinetics and reproducibility. Thrombo Haemost 1987;58:1033-6.

  6. Harris AS, Hedner P, Vilhardt H. Nasal administration by spray and drops. J Pharm Pharmacol 1987;39:932-4.

  7. Williams TDM, Lightman SL, Leadbeater MJ. Hormonal and cardiovascular responses to DDAVP in man. Clin Endocrinol 1986;24:89-96.

  8. Hammer M, Vilhardt H. Peroral treatment of diabetes insipidus with a polypeptide hormone analogue, desmopressin. J Pharmacol Exp Ther 1985;234:754-60.

  9. Cunnah D, Ross G, Besser GM. Management of cranial diabetes insipidus with oral desmopressin (DDAVP). Clin Endocrinol 1986;24:253-7.

  10. Fjellestad A, Czernichow P. Central diabetes insipidus in children. V. Oral treatment with a vasopressin hormone analogue (DDAVP). Acta Paediatr Scand 1986;75:605-10.

  11. Williams TDM, Dunger DB, Lyon CC, Lewis RJ, Taylor F, Lightman SL. Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults and children. J Clin Endocrinol Metab 1986;63:129-32.

  12. Westgren U, Wittstrom C, Harris AS. Oral desmopressin in central diabetes insipidus. Arch Dis Child 1986;61:247-50.

  13. Vilhardt H, Bie P. Antidiuretic effect of perorally administered DDAVP in hydrated humans. Acta Endocrinol (Copenh) 1984;105:474-6.

  14. Carraro A, Fano M, Porcella E, Bernareggi J, Giusti M. Trattamento del diabete insipido centrale con DDAVP per via orale. Confronto con il trattamento per via endonasale. Minerva Endocrinol 1991;16:141-5.

  15. Rampazzo AL, Boscaro M, Mantero F, Piccito R. Valutazione clinica della desmopressina (DDAVP) nel diabete insipido: soluzione vs compresse. Minerva Endocrinol 1992;17:37-41.

  16. Carrero A, Fano M, Cuttica M, Bernareggi V, Giusti M, Giordano G. Trattamento a lungo termine del diabete insipido centrale con DDAVP per via orale. Minerva Endocrinol 1992;17:189-93.

  17. Merola B, Caruso E, Chiara G, et al. Efficacia e tollerabilita della desmopressina in formulazione orale nel trattamento del diabete insipido centrale. Minerva Med 1992;83:805-13.

  18. Carrero A, Giusti M. Desmopressina orale nel trattamento del diabete insipido centrale. Minerva Med 1993;84:563.

  19. Fjellestad PA, Paulsen O, Abensour d’Agay L, Lundin S, Czernichow P. Central diabetes insipidus oral treatment with DDAVP. Regulatory Peptides 1993;45:303-7.

  20. Lam KS, Wat MS, Cho KL, Ip TP, Pang RW, Kumana CR. Pharmacokinetics, pharmacodynamics, long term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus. Br J Clin Pharmacol 1996;42:379-85.

  21. Boulgourdjian EM, Martínez AS, Ropelato MG, Heinrich JJ, Bergadá C. Oral desmopressin treatment of central diabetes insipidus in children. Acta Paediatr 1997;86:1261-2.

  22. Fjellestad-Paulsen A, Laborde K, Kindermans C, Czernichow P. Water-balance hormones during long-term follow-up or oral DDAVP treatment in diabetes insipidus. Acta Paediatr 1993;82:752-7.




2020     |     www.medigraphic.com